Abstract
Objective To assess the efficacy and safety of chemoradiotherapy combined with sodium glycididazole (CMNa) for the patients with esophageal carcinoma by conducting a Meta-analysis. Methods By searching Chinese Biomedical Database, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, PubMed, Cochrane Library and EMBase, we collected randomized clinical controlled studies (RCTs) of chemoradiotherapy combined with CMNa and control group without CMNa in the treatment of esophageal carcinoma. According to the inclusion and exclusion criteria, data extraction and quality assessment were done by two researchers independently. Meta-analysis was performed by using Revman 5.3. Results A totle of 4 RCTs involving 262 patients were included. The Meta-analysis results showed that chemoradiotherapy combined with CMNa group had better complete remission rate (OR=2.09, 95%CI: 1.24-3.54, Z=2.76, P=0.006) and overall response rate (OR=2.75, 95%CI: 1.39-5.44, Z=2.90, P=0.004) than the control group, with significant differences. The 1-year survival rates of the two groups were similar, with no significant difference (OR=1.85, 95%CI: 0.94-3.64, Z=1.77, P=0.08). There were no significant differences in the incidence rates of adverse reactions such as gastrointestinal adverse reaction (OR=0.92, 95%CI: 0.49-1.70, Z=0.28, P=0.78), bone marrow suppression (OR=0.69, 95%CI: 0.39-1.19, Z=1.33, P=0.18), liver damage (OR=0.93, 95%CI: 0.48-1.79, Z=0.23, P=0.82), radioactive esophagitis (OR=1.07, 95%CI: 0.58-2.00, Z=0.22, P=0.82 ), radioactive pneumonia (OR=0.76, 95%CI: 0.29-1.98, Z=0.56, P=0.57) and radioactive skin lesion (OR=1.11, 95%CI: 0.51-2.43, Z=0.26, P=0.80). Conclusion In the treatment of esophageal carcinoma, chemoradiotherapy combined with CMNa has a good short-term effect, and does not increase the occurrence of adverse reactions. Key words: Esophageal neoplasms; Radiation-sensitizing agents; Meta-analysis; Chemoradiotherapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
